Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Journal of the American Academy of Dermatology|June 25, 2019
Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse eventsLinda Chan, Shelley J E Hwang, Karen Byth, et al.
The Australasian Journal of Dermatology|February 22, 2025
Improving Cardiovascular Outcomes in the Psoriasis Cohort. Psoriasis and Cardiovascular Disease-Clinician Knowledge, Practice and PerceptionsAnnika Smith, Belinda Lai, Sarah Zaman, et al.
Journal of the American Academy of Dermatology|January 23, 2016
Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohortShelley Ji Eun Hwang, Giuliana Carlos, Deepal Wakade, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 2, 2023
Long-term cost-effectiveness of a melanoma prevention program using genomic risk information compared with standard prevention advice in AustraliaChi Kin Law, Anne E Cust, Amelia K Smit, et al.
The Australasian Journal of Dermatology|November 23, 2024
Australasian hidradenitis suppurativa management guidelinesJohn Frew, Annika Smith, Pablo Fernandez Penas, et al.
JAMA Dermatology|March 17, 2021
Efficiency of Detecting New Primary Melanoma Among Individuals Treated in a High-risk Clinic for Skin SurveillancePascale Guitera, Scott W Menzies, Elliot Coates, et al.
Lung Cancer (Amsterdam, Netherlands)|April 28, 2026
Asia-Pacific practical consensus in the management of adverse events related to amivantamab-based therapies in non-small cell lung cancerRoss A Soo, Pablo Fernandez-Penas, Molly Li, et al.
Pageof 5